Literature DB >> 27073727

Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method.

Ning Zhang1, Jia-Ning Fu2, Ting-Chao Chou3.   

Abstract

This brief article focuses on two aims: i) To investigate the in vitro pharmaco-dynamic interactions of combining synthetic potent microtubule targeting anticancer agent, Fludelone (FD) with cyto-protective agent, Panaxytriol (PXT) derived from Panax ginseng, and ii) To illustrate step-by-step operation for conducting two-drug combination in vitro using the combination index method, in terms of experimental design, data acquisition, computerized simulation and data interpretation. The Chou-Talalay method for drug combination is based on the median-effect equation, which provides the theoretical basis for the combination index (CI)-isobologram equation that allows quantitative determination of drug interactions, where CI<1, =1, and >1 indicates synergism, additive effect and antagonism, respectively. Based on these algorithms, computer software, CompySyn, is used for determining synergism and antagonism at all doses or effect levels simulated automatically. The use of Chou-Talalay's CI method in quantifying synergism or antagonism is increasing steadily during the past two decades, however, confusing questions and pitfalls were still frequently raised by insufficient understanding of the theory, especially reflected when researchers trying to use the computerized software to design and conduct experiments. In order to specifically address the confusions and to illustrate the practical features of this method, in this paper, a selected example is given based on our unpublished data regarding the combinational pharmacologic interactions of FD and PXT against the growth of breast cancer cell line MX-1. The step-by-step operation from experimental design to the real data analysis is illustrated. The results indicated that FD and PXT combination in vitro exerted synergistic effect when cell growth inhibition was greater than 45%, with CI ranged 0.836-0.609 for the fractional inhibition of Fa=0.50~0.90, as shown by the Fa-CI plot and by the isobologram. Thus, quantitative conclusion of synergism is obtained using the Chou-Talalay CI method, under the well-defined simple conditions for the FD and PXT combinations in vitro.

Entities:  

Keywords:  Fludelone; combination index; compusyn; panaxytriol; synergism quantification

Year:  2015        PMID: 27073727      PMCID: PMC4759401     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  20 in total

1.  The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice.

Authors:  T C Chou; O A O'Connor; W P Tong; Y Guan; Z G Zhang; S J Stachel; C Lee; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

2.  The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development.

Authors:  Ting-Chao Chou
Journal:  Am J Cancer Res       Date:  2011-08-05       Impact factor: 6.166

Review 3.  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors:  Ting-Chao Chou
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

4.  Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.

Authors:  T C Chou; X G Zhang; C R Harris; S D Kuduk; A Balog; K A Savin; J R Bertino; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

6.  Multifaceted cytoprotection by synthetic polyacetylenes inspired by the ginseng-derived natural product, panaxytriol.

Authors:  Ting-Chao Chou; Huajin Dong; Xiuguo Zhang; Xiaoguang Lei; John Hartung; Yandong Zhang; Jun Hee Lee; Rebecca M Wilson; Samuel J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-15       Impact factor: 11.205

7.  Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route.

Authors:  Ting-Chao Chou; Huajin Dong; Xiuguo Zhang; William P Tong; Samuel J Danishefsky
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

8.  Imaging induction of cytoprotective enzymes in intact human cells: coumberone, a metabolic reporter for human AKR1C enzymes reveals activation by panaxytriol, an active component of red ginseng.

Authors:  Marlin Halim; Dominic J Yee; Dalibor Sames
Journal:  J Am Chem Soc       Date:  2008-10-01       Impact factor: 15.419

9.  Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.

Authors:  T C Chou; R J Motzer; Y Tong; G J Bosl
Journal:  J Natl Cancer Inst       Date:  1994-10-19       Impact factor: 13.506

10.  A possible mechanism for the cytotoxicity of a polyacetylenic alcohol, panaxytriol: inhibition of mitochondrial respiration.

Authors:  H Matsunaga; T Saita; F Nagumo; M Mori; M Katano
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more
  50 in total

1.  Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation.

Authors:  Chaoyun Pan; Jaemoo Chun; Dan Li; Austin C Boese; Jie Li; JiHoon Kang; Anna Umano; Yunhan Jiang; Lina Song; Kelly R Magliocca; Zhuo G Chen; Nabil F Saba; Dong M Shin; Taofeek K Owonikoko; Sagar Lonial; Lingtao Jin; Sumin Kang
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

2.  Inhibition of O-GlcNAcase Sensitizes Apoptosis and Reverses Bortezomib Resistance in Mantle Cell Lymphoma through Modification of Truncated Bid.

Authors:  Sudjit Luanpitpong; Nawin Chanthra; Montira Janan; Jirarat Poohadsuan; Parinya Samart; Yaowalak U-Pratya; Yon Rojanasakul; Surapol Issaragrisil
Journal:  Mol Cancer Ther       Date:  2017-11-22       Impact factor: 6.261

3.  Synergistic lethal mutagenesis of hepatitis C virus.

Authors:  Isabel Gallego; María Eugenia Soria; Josep Gregori; Ana I de Ávila; Carlos García-Crespo; Elena Moreno; Ignacio Gadea; Jaime Esteban; Ricardo Fernández-Roblas; Juan Ignacio Esteban; Jordi Gómez; Josep Quer; Esteban Domingo; Celia Perales
Journal:  Antimicrob Agents Chemother       Date:  2019-09-30       Impact factor: 5.191

4.  Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations.

Authors:  April C Joice; Sihyung Yang; Abdelbasset A Farahat; Heidi Meeds; Mei Feng; Junan Li; David W Boykin; Michael Zhuo Wang; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

5.  Synergistic neuroprotective effect of saikosaponin A and albiflorin on corticosterone-induced apoptosis in PC12 cells via regulation of metabolic disorders and neuroinflammation.

Authors:  Xiao Li; Ruihong Hou; Xuemei Qin; Yanfei Wu; Xingkang Wu; Junsheng Tian; Xiaoxia Gao; Guanhua Du; Yuzhi Zhou
Journal:  Mol Biol Rep       Date:  2022-08-24       Impact factor: 2.742

6.  Adapalene and Doxorubicin Synergistically Promote Apoptosis of TNBC Cells by Hyperactivation of the ERK1/2 Pathway Through ROS Induction.

Authors:  Umar Mehraj; Irfan Ahmad Mir; Mahboob Ul Hussain; Mustfa Alkhanani; Nissar Ahmad Wani; Manzoor Ahmad Mir
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

7.  N(6)-methyladenosine methylation-regulated polo-like kinase 1 cell cycle homeostasis as a potential target of radiotherapy in pancreatic adenocarcinoma.

Authors:  Shotaro Tatekawa; Keisuke Tamari; Ryota Chijimatsu; Masamitsu Konno; Daisuke Motooka; Suguru Mitsufuji; Hirofumi Akita; Shogo Kobayashi; Yoshiki Murakumo; Yuichiro Doki; Hidetoshi Eguchi; Hideshi Ishii; Kazuhiko Ogawa
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

8.  Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma.

Authors:  Xi Zhang; Peng Huang; Liqiong Wang; Shu Chen; Basappa Basappa; Tao Zhu; Peter E Lobie; Vijay Pandey
Journal:  Cell Death Dis       Date:  2022-06-20       Impact factor: 9.685

9.  3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening.

Authors:  Li Wan; Jun Yin; John Skoko; Russell Schwartz; Mei Zhang; Philip R LeDuc; Carola A Neumann
Journal:  Mol Cancer Ther       Date:  2021-03-30       Impact factor: 6.261

10.  In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach.

Authors:  Brett Fleisher; Jovin Lezeau; Carolin Werkman; Brehanna Jacobs; Sihem Ait-Oudhia
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.